Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD · NASDAQ Global Select
+$0.01 today
Vol 4.93M · Avg 2.35M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-9.2%
avg -70.5%
ROIC
11.4%
avg -23.6%
ROA
6.1%
avg -23.5%
Analysis
ROIC is currently the strongest return metric at 11.4% versus its period average of -23.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas A. McCourt | Chief Executive Officer & Director | $1.54M | — | 69 | $1.90M | 1.15% |
Tammi Gaskins | Senior Vice President & Chief Commercial Officer. | $767,612.00 | — | 53 | $350,350.00 | 0.21% |
Greg Martini | Senior Vice President, Chief Financial Officer & Investor Relations | $763,356.00 | — | 37 | $297,213.00 | 0.18% |
Michael Shetzline | Chief Medical Officer, Senior Vice President and Head of Research & Drug Development | $756,701.00 | — | 67 | $658,037.00 | 0.40% |
John Minardo | Senior Vice President, Chief Legal Officer & Secretary | $717,470.00 | — | 50 | $500,498.00 | 0.30% |
Rosario Lobrutto | Vice President & Global Head of Technical Operations | — | — | — | — | — |
Jeff Ruberti | Chief Strategy Officer | — | — | — | — | — |
Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | — | — | 44 | $441,570.00 | 0.27% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$62,263.92
Sells
20
$21.99M
Net Sentiment
$21.93M
Net selling
Most Active
Silver Ronald
4 transactions
1–10 of 21
Analysis
Insiders reported 1 buys worth $62,263.92 and 20 sells worth $21.99M over the last 12 months. That adds up to net selling of $21.93M. Silver Ronald was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -0.2% | -2.8% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.2% over three years. Forward estimates point to Revenue at -2.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$775.07M
NeuroPace, Inc.
NASDAQ:NPCE
$518.91M
Canopy Growth Corporation
NASDAQ:CGC
$402.02M
Silence Therapeutics plc
NASDAQ:SLN
$324.73M
Cellectis S.A.
NASDAQ:CLLS
$316.31M
Alpha Teknova, Inc.
NASDAQ:TKNO
$275.58M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$208.55M
Aurora Cannabis Inc.
NASDAQ:ACB
$165.68M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.32M
Genelux Corporation
NASDAQ:GNLX
$108.90M
Who manages IRWD?
Ironwood Pharmaceuticals, Inc. (IRWD) lists 8 active executives. The top listed executive is Greg Martini, Senior Vice President, Chief Financial Officer & Investor Relations.
Are IRWD insiders buying or selling?
Recent insider activity shows net selling of $34.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.